Latest stories

  • in

    US Supreme Court turns down Sanofi appeal to revive EpiPen suit against Viatris

    US Supreme Court turns down Sanofi appeal to revive EpiPen suit against Viatris

    Washington: The U.S. Supreme Court on Monday declined to hear a bid by Sanofi SA to revive its antitrust lawsuit accusing rival pharmaceutical company Viatris Inc of illegally monopolizing the market with its EpiPen auto-injector, a device used to treat severe allergic reactions. The justices turned away Sanofi’s appeal of a lower court’s ruling rejecting the […] More

  • in

    AstraZeneca, Sanofi, Sobi simplify contractual agreements for Nirsevimab

    AstraZeneca, Sanofi, Sobi simplify contractual agreements for Nirsevimab

    Paris. Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus (nirsevimab) in the United States (U.S.). Under the new and updated arrangements, Sobi will terminate its participation agreement with AstraZeneca, and Sanofi and AstraZeneca will update the Collaboration Agreement so that Sanofi has full commercial control of nirsevimab in the […] More